◎ Sugi Atlas

Atlas / Drug / Somatropin

Somatropin

drug
On this page

Also known as CB-311DA-3002GenotonormGenotropinGenotropin goquickGenotropin kabipenGenotropin kabiquickGenotropin kabivialGenotropin miniquickGrowth hormoneGrowth hormone (human)Genotropin [rdna origin]HghHsb-hghHuman growth hormoneHumatropeHypertropinHumatropenLY-137998LY137998

Summary

Somatropin (CHEMBL1201621) is an approved protein (ATC H01AC01) targeting GHR; indicated across 51 conditions including chronic kidney disease and endocrine system disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: H01AC01
  • Targets: 1 (GHR)
  • Indications: 51 conditions
  • Clinical trials: 298

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201621
NameSomatropin
TypeProtein
Max phase4
ATCH01AC01

Also known as: CB-311, DA-3002, Genotonorm, Genotropin, Genotropin goquick, Genotropin kabipen, Genotropin kabiquick, Genotropin kabivial, Genotropin miniquick, Growth hormone, Growth hormone (human), Genotropin [rdna origin]

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
GHRGrowth hormone receptorAgonist9.040%P10912

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): GHR.

Top Reactome pathways

2 total, by targets touching each:

PathwayTargetsGenes
Prolactin receptor signaling1GHR
Growth hormone receptor signaling1GHR

Dominant GO biological processes

GO termTargets
endocytosis1
cell surface receptor signaling pathway via JAK-STAT1
positive regulation of cell population proliferation1
response to gravity1
hormone-mediated signaling pathway1
cytokine-mediated signaling pathway1
taurine metabolic process1
receptor internalization1
response to food1
regulation of response to nutrient levels1
response to estradiol1
cellular response to insulin stimulus1
cellular response to hormone stimulus1
regulation of multicellular organism growth1
positive regulation of multicellular organism growth1

Indications & clinical

Indications

51 indications (15 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
chronic kidney disease4MONDO:0005300EFO:0003884
endocrine system disorder4MONDO:0005151EFO:0001379
HIV infectious disease4MONDO:0005109EFO:0000764
pituitary dwarfism4MONDO:0006909EFO:1001109
short bowel syndrome4MONDO:0015183MONDO:0015183
pituitary gland disorder4MONDO:0003381EFO:0009607
Turner syndrome4MONDO:0019499MONDO:0001967
Prader-Willi syndrome4MONDO:0008300MONDO:0008300
fetal growth restriction3MONDO:0005030EFO:0000495
heart failure3MONDO:0005252EFO:0003144
obesity disorder3MONDO:0011122EFO:0001073
cardiovascular disorder3MONDO:0004995EFO:0000319
hypopituitarism3MONDO:0005152EFO:0001380
diabetes mellitus3MONDO:0005015EFO:0000400
HIV wasting syndrome3MONDO:0005797EFO:0007312
hereditary endocrine growth disease3MONDO:0015514MONDO:0015514
cystic fibrosis3MONDO:0009061MONDO:0009061
Noonan syndrome3MONDO:0018997MONDO:0018997
osteogenesis imperfecta3MONDO:0019019MONDO:0019019
juvenile idiopathic arthritis3MONDO:0011429EFO:0002609
spinal cord injury3MONDO:0043797MONDO:0043797
infertility disorder2MONDO:0005047EFO:0000545
Crohn disease2MONDO:0005011EFO:0000384
disease of the tendon2MONDO:0100010EFO:1001434
cirrhosis of liver2MONDO:0005155EFO:0001422
tibia fracture2MONDO:0005320EFO:0003944
spinal muscular atrophy2MONDO:0001516EFO:0008525
burn2MONDO:0043519EFO:0009516
osteoarthritis, knee2MONDO:0005416EFO:0004616
brain injury2MONDO:0043510MONDO:0043510
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
pseudohypoparathyroidism2MONDO:0019992MONDO:0007078
mucopolysaccharidosis type 62MONDO:0009661MONDO:0009661
mucopolysaccharidosis type 22MONDO:0010674MONDO:0010674
metabolic dysfunction-associated steatotic liver disease2MONDO:0013209EFO:0003095
bone fracture2MONDO:0005315EFO:0003931
mucopolysaccharidosis2MONDO:0019249MONDO:0019249
facioscapulohumeral muscular dystrophy1MONDO:0001347Orphanet:269
female infertility1MONDO:0021124EFO:0008560

12 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 298.

Phase distribution

PhaseTrials
PHASE379
Not specified79
PHASE248
PHASE443
PHASE127
PHASE2/PHASE314
PHASE1/PHASE25
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05681299PHASE4RECRUITINGEffects of GH and Lirglutide on AgRP
NCT00184769PHASE4COMPLETEDGrowth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
NCT00194883PHASE4SUSPENDEDEffect of Cytokines on Growth of Children With Chronic Kidney Failure
NCT00194961PHASE4TERMINATEDEffect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease
NCT00206375PHASE4TERMINATEDGrowth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism
NCT00256126PHASE4COMPLETEDPredictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
NCT00266656PHASE4COMPLETEDLong-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome
NCT00287677PHASE4COMPLETEDInduction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients
NCT00307411PHASE4UNKNOWNEffect of Growth Hormone in Metabolic Syndrome
NCT00373386PHASE4COMPLETEDGrowth Hormone and Endothelial Function in Children
NCT00432263PHASE4WITHDRAWNTreatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury.
NCT00490191PHASE4COMPLETEDComparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency
NCT00519844PHASE4COMPLETEDGrowth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction
NCT00537914PHASE4COMPLETEDSafety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)
NCT00555009PHASE4TERMINATEDTreatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury
NCT00567385PHASE4COMPLETEDLiquid Somatropin Formulation in Children With Growth Hormone Deficiency
NCT00638053PHASE4TERMINATEDA Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury
NCT00742157PHASE4TERMINATEDEvaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)
NCT00840944PHASE4UNKNOWNA 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
NCT00957671PHASE4COMPLETEDAnterior Pituitary Hormone Replacement in Traumatic Brain Injury
NCT01052623PHASE4UNKNOWNStatus of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
NCT01066052PHASE4COMPLETEDGrowth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
NCT01157793PHASE4COMPLETEDA Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
NCT01245374PHASE4COMPLETEDNorditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
NCT01380366PHASE4COMPLETEDrHGH and Intestinal Permeability in Intestinal Failure
NCT01518062PHASE4COMPLETEDSafety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
NCT01562834PHASE4COMPLETEDEffect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients
NCT01697644PHASE4COMPLETEDGrowth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation
NCT01698944PHASE4TERMINATEDCardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency
NCT01734447PHASE4COMPLETEDLong Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation
NCT01734486PHASE4COMPLETEDGrowth Response in Girls With Turner Syndrome
NCT01853566PHASE4COMPLETEDEffects of Growth Hormone Administration on Muscle Strength and Body Composition in Men Over 50 Years Old
NCT01859949PHASE4COMPLETEDLong Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)
NCT01901666PHASE4UNKNOWNAssessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission
NCT02195947PHASE4COMPLETEDAntagonist Protocol in Poor Responders
NCT02311894PHASE4COMPLETEDA Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
NCT02766764PHASE4UNKNOWNCombined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI
NCT03015909PHASE4COMPLETEDEvaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.
NCT03027843PHASE4UNKNOWNThe Effect of Growth Hormone in Assisted Reproductive Technology Clinical Outcome of Poor Responder
NCT03616509PHASE4COMPLETEDGH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

1 molecules share ≥1 primary target. Top 1 by shared-target count:

MoleculeSourceStatusShared targets
EnzalutamidePubChemApprovedGHR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot